These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 11205155

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease.
    Gerlach M, Double KL, Ben-Shachar D, Zecca L, Youdim MB, Riederer P.
    Neurotox Res; 2003; 5(1-2):35-44. PubMed ID: 12832223
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Potential sources of increased iron in the substantia nigra of parkinsonian patients.
    Gerlach M, Double KL, Youdim MB, Riederer P.
    J Neural Transm Suppl; 2006; (70):133-42. PubMed ID: 17017520
    [Abstract] [Full Text] [Related]

  • 5. The relevance of iron in the pathogenesis of Parkinson's disease.
    Sian-Hülsmann J, Mandel S, Youdim MB, Riederer P.
    J Neurochem; 2011 Sep; 118(6):939-57. PubMed ID: 21138437
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Iron transport in Parkinson's disease.
    Hirsch EC.
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S209-11. PubMed ID: 20082992
    [Abstract] [Full Text] [Related]

  • 9. The role of transition metals in the pathogenesis of Parkinson's disease.
    Kienzl E, Puchinger L, Jellinger K, Linert W, Stachelberger H, Jameson RF.
    J Neurol Sci; 1995 Dec; 134 Suppl():69-78. PubMed ID: 8847547
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Iron-binding characteristics of neuromelanin of the human substantia nigra.
    Double KL, Gerlach M, Schünemann V, Trautwein AX, Zecca L, Gallorini M, Youdim MB, Riederer P, Ben-Shachar D.
    Biochem Pharmacol; 2003 Aug 01; 66(3):489-94. PubMed ID: 12907248
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Glutathione, iron and Parkinson's disease.
    Bharath S, Hsu M, Kaur D, Rajagopalan S, Andersen JK.
    Biochem Pharmacol; 2002 Sep 01; 64(5-6):1037-48. PubMed ID: 12213603
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Mössbauer spectroscopy and ELISA studies reveal differences between Parkinson's disease and control substantia nigra.
    Galazka-Friedman J, Bauminger ER, Koziorowski D, Friedman A.
    Biochim Biophys Acta; 2004 Mar 02; 1688(2):130-6. PubMed ID: 14990343
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.